Given a genetic confirmation of Lynch Syndrome, risk reduction surgery should be performed. This is especially true with those Lynch cohorts with MSH6 mutations or MSH2, as these have the highest risk---or even the exclusive presentation with--endometrial cancers. Once the uterus has been removed, t...

Women with Lynch syndrome can have up to a 40-60% lifetime risk of endometrial cancer depending on the mutation (Cancer Control 2009). A small number (1%) of women in the Lynch syndrome registry of over 1000 pts reported tamoxifen or raloxifene, so the effect of SERMs on this population is not known...